Compare PESI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | ACIU |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 213.3M |
| IPO Year | 1996 | 2015 |
| Metric | PESI | ACIU |
|---|---|---|
| Price | $12.19 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 195.7K | ★ 244.5K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,000.00 | N/A |
| Revenue This Year | $34.62 | $635.38 |
| Revenue Next Year | $77.02 | $232.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $1.45 |
| 52 Week High | $16.50 | $4.00 |
| Indicator | PESI | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 61.19 |
| Support Level | $11.01 | $3.18 |
| Resistance Level | $12.37 | $3.43 |
| Average True Range (ATR) | 0.71 | 0.20 |
| MACD | 0.20 | 0.07 |
| Stochastic Oscillator | 86.11 | 81.91 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.